Pain News and Research

Latest Pain News and Research

Unapproved codeine sulfate tablets: FDA warns four companies to stop marketing

The U.S. Food and Drug Administration today warned four companies that they must stop marketing unapproved codeine sulfate tablets. These drugs are opioid analgesics, commonly called narcotics, that are widely used to treat pain.

14 Oct 2009

Positive results from BioMimetic Therapeutics' Phase III trial comparing Augment Bone Graft to autograft

BioMimetic Therapeutics, Inc. today announced positive top-line results from its North American pivotal (Phase III) randomized controlled trial comparing its fully synthetic, off-the-shelf bone growth factor product, Augment Bone Graft (“Augment”), to autograft for use in hindfoot and ankle fusion surgery.

14 Oct 2009

Endoscopic surgery reduces postoperative discomfort and recovery time

Endoscopic surgery has steadily gained in popularity since it was developed in the 1980s. Dr. Richard Siegfried has teamed with Dr. Louis Quartararo one of only a handful of surgeons who have been trained to perform endoscopic surgery on the spine.

14 Oct 2009

Meda Pharmaceuticals introduces Onsolis for treating breakthrough cancer pain

Meda Pharmaceuticals Inc. today announced the launch of Onsolis(TM)(fentanyl buccal soluble film) in the U.S. for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

13 Oct 2009

HyperBranch Medical Technology's NuSeal 30 hernia mesh fixation sealant product receives CE Mark

HyperBranch Medical Technology, Inc. announced today that it has received a CE Mark for its NuSeal 30 hernia mesh fixation sealant product. NuSeal 30 is used in hernia procedures to adhere the mesh. NuSeal 30 provides for secure mesh placement, minimizes pain caused by other fixation devices and gradually degrades as the body heals.

13 Oct 2009

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Provectus Pharmaceuticals, Inc., a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.

13 Oct 2009

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

Merck Frosst Canada Ltd. announced today that its new diabetes treatment, JANUMET(TM) (sitagliptin/metformin HCI, MSD), has received Notice of Compliance (NoC) in Canada.

13 Oct 2009

Thomson Reuters's NeoFax deployed at the University of Kansas Hospital for electronic neonatal drug dosing

The University of Kansas Hospital has deployed NeoFax(®) from Thomson Reuters to provide physicians, nurses, and pharmacy staff in its neonatal intensive care unit with electronic drug dosing, interaction checking, and reference information.

13 Oct 2009

Itech Medical displays Muscle Pattern Recognition tool at BioContact Quebec 2009

iTech Medical, Inc. (OTCBB: IMSU) (FWB: 0IM), an information technology company, showcased the Company’s proprietary information technology platform, Muscle Pattern Recognition (MPR), at BioContact Quebec 2009.

13 Oct 2009

Strengthen key muscles in the foot to improve overall performance

With summer weather finally gone, more Canadians will spend hours at the gym sculpting their muscles, but most will neglect one of the most important ones - the foot. Recent studies show neglecting the feet leads to chronic foot, knee, back, and joint pain. By strengthening key muscles in the foot, a person can improve their overall performance, energy and pain.

13 Oct 2009

Acupuncture can help prevent caesarean delivery

Debra Betts, an international expert, educator and author of the Essential Acupuncture for Pregnancy and Childbirth will be presenting a workshop for dulas, midwives and acupuncturists in Vancouver, October 13th and 14th.

13 Oct 2009

Women abused by intimate partners suffer higher rates of medical maladies

Women abused by intimate partners suffer higher rates of a wide variety of doctor-diagnosed medical maladies compared to women who were never abused, according to a new study of more than 3,000 women.

13 Oct 2009

Legendary coach helps raise awareness on osteoarthritis

After leading the U.S. men’s basketball team to Olympic gold last year and two weeks before the start of his 30th season as head coach of Duke University’s men’s basketball team, Mike Krzyzewski (Coach K), 61, is teaming up with the Arthritis Foundation to help raise awareness of the disease that nearly ended his coaching career 10 years ago.

13 Oct 2009

Health Robotics' i.v.STATION robot wins the Area Science Park 3L 3T Innovation Award

Health Robotics today announced the manufacturing, shipment, and subsequent field installation of the first five i.v.STATION post-prototype robots in the United States of America and in Spain within the September to November timeframe this year; concurrently, Health Robotics also made the announcement of its i.v.STATION robot's winning of the Area Science Park 3L 3T Innovation Award, which is given to the best technology product across all industries.

12 Oct 2009

B. Braun Medical announces agreement with HealthTrust to provide pain management products

B. Braun Medical Inc. (B. Braun) has announced an expanded agreement with HealthTrust Purchasing Group (HealthTrust) to provide pain management products to HealthTrust's membership.

From B. Braun Melsungen AG 12 Oct 2009

QRxPharma signs contractual agreement with Patheon

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today a contractual agreement with Patheon to manufacture clinical supplies of QRxPharma's controlled release Dual-Opioid(TM) formulation (MoxDuo(TM)CR). MoxDuo(TM)CR is designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic).

12 Oct 2009

FDA grants marketing approval for CSL Behring's Berinert C1-Esterase Inhibitor

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Berinert® C1-Esterase Inhibitor, Human for the treatment of acute abdominal or facial attacks of hereditary angioedema (HAE), a rare and serious genetic disorder, in adult and adolescent patients. Berinert is the first and only therapy approved for this indication in the U.S.

12 Oct 2009

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Nektar Therapeutics presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona.

12 Oct 2009

U.S. women with RA feel less self-confident in their sex-life, reveals survey

A new survey of U.S. women living with rheumatoid arthritis (RA) published today reveals that RA has a clear emotional impact on people living with the disease, with loss of self-confidence seen in their sex lives, in the workplace, and in their social lives.

12 Oct 2009

VitalWear partners with XBACK Bracing Services to deliver innovative products

VitalWear, Inc. (www.vitalwear.com), a leader in thermal compression medical devices announced that they have formed a partnership with XBACK Bracing Services (www.xbackbrace.com) revolutionizing the bracing and thermal therapy markets. (www.thexbackvwsolution.com)

12 Oct 2009